Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lille
Clinical trial register · France

Clinical Trials in Lille, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 68 Marseille 36 Bordeaux 35 Montpellier 32 Lille 31
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Lille138 Janssen Research & Development, LLC43 Hoffmann-La Roche40 AstraZeneca36 Assistance Publique - Hôpitaux de Paris34 Clear sponsor filter
Site location
Paris68 Marseille36 Bordeaux35 Montpellier32 Lille31
All 73 locations
Target enrolment
to

Trials with a site in Lille

31 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Caen, Créteil, Lille, Marseille, Nantes, Paris, Rennes, Toulouse
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Créteil, Lille, Nantes
2026-01-13
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Limoges, Ajaccio, Amiens, Clermont-Ferrand, Grenoble, Lille, Montpellier, Nancy
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Paris
2025-11-03
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bordeaux, Clermont-Ferrand, Lille, Marseille, Nice, Nîmes, Paris, Poitiers
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Bordeaux, Brest, Le Kremlin-Bicêtre, Lille
2025-06-20
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Brest, Lille, Lorient, Paris, Pierre-Bénite, Reims, Rouen
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Béziers, Cholet, Grenoble, Lille, Montpellier, Paris, Pessac, Poitiers
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Bordeaux, Brest, Lille
2025-04-22
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Bordeaux, Lille, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy
2025-02-18
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Brest, Lille, Lyon, Marseille, Paris, Rennes
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Bordeaux, Dijon, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Bron, Lille, Nice, Paris, Tours
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Dijon, Le Mans, Lille, Montpellier, Paris, Rennes, Strasbourg, Toulouse
2024-10-09
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Angers, Bordeaux, Bron, Caen, Dijon, Lille, Marseille, Montpellier
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Angers, Brest, Dijon, Le Kremlin-Bicêtre, Le Mans, Lille, Paris, Saint-Priest-en-Jarez
2023-10-27
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Nîmes, Lille, Lyon, Grenoble, Paris
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
38
Lille, Paris, Toulouse
2023-02-23
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Caen, Chambéry, Le Mans, Lille, Rennes
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Créteil, Lille, Nantes, Nice
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice
2022-11-21
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Lille, Marseille, Montpellier
2022-07-13
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Bordeaux, Lille, Paris, Poitiers
2021-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Limoges, Toulon, Caen, Clermont-Ferrand, Dijon, Gonesse, Grenoble, Lille
2021-12-13
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Lille, Marseille, Montpellier, Paris
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Lille, Nantes, Nice, Paris, Toulouse
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Lille, Marseille, Paris, Pierre-Bénite, Toulouse, Villejuif
2020-10-30
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Lille, Lyon, Marseille, Villejuif
2019-10-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bordeaux, Lille, Lyon, Nantes, Saint-Herblain, Strasbourg, Villejuif
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Lille, Montpellier, Nantes, Nice, Nîmes, Paris, Strasbourg
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Amiens, Bron, Lille, Marseille, Strasbourg
2017-08-23
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 October 2026. https://priyalifescience.com/clinical-trials-france/city/lille

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies with a site in Lille that also match the filters currently applied.

How many clinical trials are recruiting in Lille?

11 of the 31 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lille), 31 studies
PhaseStudiesRecruitingShare
Phase 314445.2%
Phase 28325.8%
Phase 1/26319.4%
Phase 1206.5%
Phase 2/3113.2%

Most active sponsors

Lead sponsors with the most studies (Lille)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3111
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.